タンパク療法の最適化に向けた新規タンパク性アンタゴニストの創製とDDSへの展開

DOI Web Site Web Site 参考文献23件
  • 阿部 康弘
    (独)医薬基盤研究所創薬プロテオミクスプロジェクト

書誌事項

タイトル別名
  • Development of Novel DDS Technologies for Optimized Protein Therapy by Creating Functional Mutant Proteins with Antagonistic Activity
  • タンパク リョウホウ ノ サイテキカ ニ ムケタ シンキ タンパクセイ アンタゴニスト ノ ソウセイ ト DDS エ ノ テンカイ

この論文をさがす

説明

  In the post-genomic era, cytokine or antibody therapy has received attention for advanced drug therapies. Indeed, attempts are being made to develop a wide variety of therapeutic proteins for diseases including cancer, hepatitis and autoimmune conditions. Unfortunately, however, the utilization of bioactive proteins in clinical practice is often limited because of their inherent instability and pleiotropic actions in vivo. Our laboratory aims to overcome two major problems, details of which will be addressed in separate sections to follow. (i) Development of a powerful system to rapidly create functional mutant proteins (muteins) with enhanced receptor affinity and receptor specificity using a phage display technique (biological DDS). (ii) Establishment of a novel polymer-conjugation system to dramatically improve in vivo stability and selectively of bioactive proteins (polymeric DDS). We are currently attempting to combine both approaches to create a protein-drug innovation system to further promote pharmaco-proteomic-based drug development. In this review, we will describe DDS-based technology for creating functional mutants for advanced medical applications, using tumor necrosis factor-alpha (TNF) as an example.<br>

収録刊行物

  • 薬学雑誌

    薬学雑誌 129 (8), 933-939, 2009-08-01

    公益社団法人 日本薬学会

参考文献 (23)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ